Version history

{
  "session_id": "sess_SDA-2026-04-16-gap-pubmed-20260410-180503-a7a03974_20260416-134419",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"title\": \"Tau Dendritic Missorting as Gain-of-Toxic-Function Primes Neurons for Aβ-Independent Degeneration\",\n      \"mechanism\": \"Aβ initiates tau missorting from axons to dendrites where it disrupts NMDA receptor trafficking and spine stability, creating a self-sustaining toxic state that persists after Aβ removal.\",\n      \"target_gene\": \"MAPT\",\n      \"confidence_score\": 0.72,\n      \"novelty_score\": 0.65,\n      \"feasibility_score\": 0.58,\n      \"impact_score\": 0.82,\n      \"composite_score\": 0.70,\n      \"testable_prediction\": \"Conditional MAPT deletion after Aβ clearance in 3xTg mice will determine whether residual cognitive deficits require ongoing tau missorting maintenance.\",\n      \"skeptic_concern\": \"Tau missorting may be a downstream epiphenomenon rather than a causal driver of therapeutic failure; bidirectional relationship with Aβ complicates intervention timing.\"\n    },\n    {\n      \"rank\": 2,\n      \"title\": \"Aβ-Induced Lysosomal Dysfunction Converts Tau Into Proteolysis-Resistant Seed-Competent Conformations\",\n      \"mechanism\": \"Aβ-mediated lysosomal permeabilization releases tau fragments that undergo conformational change into self-propagating seeds resistant to normal degradation, making them impervious to anti-Aβ approaches.\",\n      \"target_gene\": \"CTSD\",\n      \"confidence_score\": 0.65,\n      \"novelty_score\": 0.70,\n      \"feasibility_score\": 0.52,\n      \"impact_score\": 0.78,\n      \"composite_score\": 0.68,\n      \"testable_prediction\": \"Lysosomal stabilization in APP/PS1 mice via cysteamine bitartrate will test whether preventing tau conformational change abrogates seeding while anti-Aβ therapy remains effective.\",\n      \"skeptic_concern\": \"Distinguishing primary lysosomal dysfunction from secondary effects of existing pathology in vivo remains technically challenging.\"\n    },\n    {\n      \"rank\": 3,\n      \"title\": \"Astrocyte Aβ Sensing Triggers Exosome-Mediated Tau Propagation That Bypasses Neuronal Aβ Dependency\",\n      \"mechanism\": \"Aβ-activated astrocytes release tau-laden exosomes that spread pathology to connected neurons, establishing a propagation circuit that operates independently of ongoing Aβ production.\",\n      \"target_gene\": \"GFAP\",\n      \"confidence_score\": 0.60,\n      \"novelty_score\": 0.72,\n      \"feasibility_score\": 0.48,\n      \"impact_score\": 0.75,\n      \"composite_score\": 0.65,\n      \"testable_prediction\": \"Selective astrocyte-specific Rab27a knockout in iPSC-AD models will test whether blocking exosome release prevents tau spreading when Aβ is present.\",\n      \"skeptic_concern\": \"Astrocyte heterogeneity and lack of human-relevant models limit translation from rodent systems.\"\n    }\n  ],\n  \"consensus_points\": [\n    \"Aβ-tau synergy represents a credible mechanistic framework for explaining anti-Aβ trial failures independent of trial design or patient selection issues\",\n    \"Tau-mediated gain-of-toxic-function beyond its normal axonal roles is essential for understanding the Aβ contradiction\",\n    \"The initiating event (Aβ) and maintaining drivers (tau propagation) require distinct therapeutic approaches\"\n  ],\n  \"dissent_points\": [\n    \"Whether tau missorting is a cause or consequence of Aβ toxicity remains debated, with implications for therapeutic target validity\",\n    \"The relative contribution of neuronal versus glial mechanisms to Aβ-tau synergy is contested, with different groups emphasizing cell-type specific hypotheses\"\n  ],\n  \"debate_summary\": \"The central contradiction—that Aβ targeting fails despite its presumed initiating role—resolves mechanistically through tau gaining toxic functions that become Aβ-independent once established. Three convergent hypotheses (tau missorting, lysosomal dysfunction-driven tau conformational change, and astrocyte exosome propagation) all predict that anti-Aβ monotherapy fails because tau pathology becomes self-sustaining after Aβ-induced priming. The therapeutic implication is that future trials must either target tau conversion/seeding directly or combine anti-Aβ with anti-tau approaches, with timing being critical given that earlier intervention may still prevent tau from achieving independence.\"\n}\n```",
  "tokens_used": "1053"
}